SHANGHAI, China and CUPERTINO, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, today announced that management will present at the Piper Jaffray 27th Annual Healthcare Investor Conference to be held in New York City on December 1-2, 2015, and will be available for one-on-one meetings throughout the conference.
Investor Presentation: Friday, December 1, 11:30-11:50 EST
Location: The New York Palace Hotel, NY
Presenter: Yihong Yao, PhD, Chief Scientific Officer
To arrange one-on-one meetings with Company management, please contact vivian.chen@grayling.com. Following the conference, an archived presentation will be available on the Company website here: http://www.cellbiomedgroup.com/investor-relations/presentations/.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases. Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our GMP facilities in China, consisting of nine independent cell production lines, are designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
